Jim Stansel
James Stansel is Executive Vice President, General Counsel and Corporate Secretary of the Pharmaceutical Research and Manufacturers of America (PhRMA), where he is responsible for overseeing the organization’s legal team and science and regulatory advocacy department in supporting PhRMA’s policy, advocacy and science priorities and in the development of sound legal policies impacting the pharmaceutical industry.
The Federal Trade Commission (FTC) takes important action to highlight and curb PBM abuses
Correcting the record: IRA’s government price setting provisions are unconstitutional
FDA should remain the authority on the safety and effectiveness of medicines
Pass-through rebates do not violate non-interference clause but they do increase savings for seniors
Long-awaited FDA guidance addresses one key obstacle to value-based contracting
Jim Stansel